Home > Insider Trading > Filing (0001104659-18-062810)

Filing Details

Accession Number:: 0001104659-18-062810
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-10-18 17:03:41
Reporting Period:: 2018-10-16

Accepted Time:: 2018-10-18 17:03:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1615219	Flex Pharma Inc.	FLKS	()	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1543245	Longwood Fund Ii, L.p.	C/O Flex Pharma, Inc. 800 Boylston Street Boston MA 02199		No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-10-16	3,212,861	$0.92	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.70 to $1.33, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
Represents 2,697,264 shares sold by Longwood Fund II, L.P. ("Longwood Fund II") and 515,597 shares sold by Longwood Fund III, L.P. ("Longwood Fund III").
Longwood Fund II GP, LLC is the General Partner of Longwood Fund II and Longwood Fund III GP, LLC is the General Partner of Longwood Fund III. Christoph Westphal, M.D., Ph.D. and Richard Aldrich (collectively, the "Managers") are managers of Longwood Fund II GP, LLC and Longwood Fund III GP, LLC. The Managers have delegated their voting and dispositive power with respect to the Issuer's securities held by Longwood Fund II and Longwood Fund III (the "Longwood Shares") to a committee comprised of three members, two of which such members include the Managers (the "Longwood Committee").
The Longwood Committee approves investment and voting decisions by a majority vote, and no individual member has sole control or voting power over the Longwood Shares. Each of Longwood Fund II GP, LLC, Longwood Fund III GP, LLC, the Managers and the members of the Longwood Committee disclaim beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.